Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
about
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesReduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Busulfan in hematopoietic stem cell transplantationComparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transferInterstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Pharmacokinetics of high-dose chemotherapy.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsReview of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and MBetter leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Safety of conditioning agents for allogeneic haematopoietic transplantation.Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area.Dosing algorithm revisit for busulfan following IV infusion.Altered gene expression in busulfan-resistant human myeloid leukemiaIntravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation.Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with beta-thalassemia.
P2860
Q33566475-EA9F3B77-BCCA-4DC9-BF20-E2A7A47A4011Q33680218-CF83D801-D1DD-432F-9CFF-F3E1CC11BCE1Q33737884-11BAC24D-D6BA-4FC5-A5D7-BA2337735970Q33978951-A3E08472-B318-4E3A-9D49-2D23392A8893Q34314268-0C7B3AC0-4855-4B66-867C-8AB85EF8E2E9Q34409335-659F5A6C-6930-460F-A19F-90EE16439096Q34479575-A56CA584-A764-4BD0-B11D-ED278BAA3F79Q34505185-C7857CB5-F520-4E66-8830-4653E1326717Q34668052-DC1421F1-88B4-4354-804D-BBFC2020DCDCQ35085078-9F03C574-762B-439C-8CE9-8328E15C0365Q35133845-C0E6F8C3-48A8-4846-9C26-34B93CC0508CQ35136616-B8A1B767-8D5B-48B8-A0A5-287825BA904DQ35597047-955EBBA4-2EDD-405B-B9B5-5F9ED457DDB3Q36125427-AF325C0C-5941-4B40-A014-3336BA87879FQ36742108-009BEAD5-2A19-45CE-ACCA-BCDFF3B68A58Q36920394-2E3E73CE-D0D5-4853-A65E-84834208FA6DQ37370649-7D7E3F0A-37C6-4E7F-9141-23166887E411Q37370651-2EC5F495-33C9-4AF6-82E6-D9B9750248B3Q37510948-5F5D23BE-1671-4671-A9C5-E29BD3050487Q37738997-CB687684-47DC-4DFC-9B84-0CF769CCBBC6Q37828009-1FB972E6-95C3-4D8D-A27C-FECBF02CEE95Q38060264-099F30B2-FD4A-4F5F-8F08-252FBE1891E8Q38248427-67BC1200-C289-41D6-9EAD-2B16990F5A5CQ39743914-BCB2048F-6AFA-4545-9333-7671CD93C9DAQ40545854-9EDBB6CF-20E2-4478-941A-21B5354B196DQ41621632-8BF8FEB5-8ED9-4CA6-BDB3-9BECF0FF32C8Q41885757-1E0FFCF5-3633-4AC0-82FB-FF1B68F25629Q42175192-760303D9-8E38-41B6-891A-5CB3AECD3672Q42744573-A0C7D2BC-6187-467E-A7E6-661325187046Q43429437-F4ADF740-A722-4BF1-BD20-FEA406BEAAE1Q44586681-E81D7FE7-D9C7-4DC9-9C5C-6646BEBBE283Q44693069-25EB20BD-35F8-4E91-9270-0006D5E5A4D0Q44830422-675D70E5-CDBF-41BA-AC85-65E5C5E36CDEQ45044487-56A74E2E-B777-445A-BEC1-1924D53F04C7Q45122639-7AC442A3-3282-439E-8B54-829E0BA73D19Q45306078-D5B43C5B-EC06-41CB-95A2-2F64245F253BQ45960010-3424CFB2-F69F-4C13-8F6D-0ABE790493B7Q46131298-AD54EF3F-3677-4084-944D-2264AAF85C7CQ46244551-81494C76-4A6E-4C84-A6EA-3AE9EE17743AQ46581528-907AC6B1-8D0C-48EF-A1E6-56792C770369
P2860
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Conditioning therapy with intr ...... splantation: a phase II study.
@en
Conditioning therapy with intravenous busulfan and cyclophosphamide
@nl
type
label
Conditioning therapy with intr ...... splantation: a phase II study.
@en
Conditioning therapy with intravenous busulfan and cyclophosphamide
@nl
prefLabel
Conditioning therapy with intr ...... splantation: a phase II study.
@en
Conditioning therapy with intravenous busulfan and cyclophosphamide
@nl
P2093
P1476
Conditioning therapy with intr ...... splantation: a phase II study.
@en
P2093
Ashwin Kashyap
Borje S Andersson
Hugo Fernandez
John R Wingard
Karl G Blume
Pablo J Cagnoni
Richard E Champlin
Roy B Jones
Stefano Tarantolo
Stephen J Forman
P304
P356
10.1053/BBMT.2002.V8.PM11939604
P577
2002-01-01T00:00:00Z